The Asia-Pacific Diabetes Devices Market Size accounted for USD 2.9 Billion in 2022 and is projected to achieve a market size of USD 5.6 Billion by 2032 growing at a CAGR of 7.2% from 2023 to 2032.

Asia-Pacific Diabetes Devices Market Report Key Highlights

• Asia-Pacific diabetes devices market revenue is expected to increase by USD 5.6 Billion by 2032, with a 7.2% CAGR from 2023 to 2032
• Diabetes is a major health issue in the Asia-Pacific region, with an estimated 114.4 million people living with the disease in 2021
• The number of people with diabetes in the region is projected to increase to 154.8 million by 2045
• The insulin pump segment in the APAC diabetes devices market is also growing, with a CAGR of 11% projected between 2023 and 2032
• Growing focus on personalized medicine and precision diabetes management drives the Asia Pacific diabetes devices market size

Diabetes devices are medical devices used to manage diabetes, a chronic condition that affects the way the body processes blood sugar. These devices include blood glucose meters, continuous glucose monitoring systems, insulin pens, insulin pumps, and others. The primary goal of these devices is to help people with diabetes monitor their blood sugar levels, administer insulin, and manage their condition effectively.

The diabetes device market has grown significantly in recent years due to the increasing prevalence of diabetes worldwide. According to the International Diabetes Federation, an estimated 463 million adults (aged 20-79 years) were living with diabetes in 2019, and this number is projected to increase to 700 million by 2045. The Asia-Pacific region has the highest number of people with diabetes, with China and India being the most affected countries. As a result, the demand for diabetes devices industry in this region is expected to continue to grow. Several factors are driving the growth of the diabetes devices market, including the increasing adoption of digital health technologies, rising awareness about diabetes management, and the development of innovative products.

Asia-Pacific Diabetes Devices Market Trends

APAC Diabetes Devices Market Drivers

• Increasing prevalence of diabetes worldwide
• Growing adoption of digital health technologies
• Rising awareness about diabetes management
• Development of innovative products
• Increasing demand for minimally invasive and non-invasive diabetes devices

APAC Diabetes Devices Market Restraints

• High cost of diabetes devices and treatment
• Stringent regulatory requirements

APAC Diabetes Devices Market Opportunities

• Rising demand for remote patient monitoring and telemedicine
• Growing focus on personalized medicine and precision diabetes management

APAC Diabetes Devices Market Report Coverage

Market	Asia-Pacific Diabetes Devices Market
Asia Pacific Diabetes Devices Market Size 2022	USD 2.9 Billion
Asia Pacific Diabetes Devices Market Forecast 2032	USD 5.6 Billion
Asia Pacific Diabetes Devices Market CAGR During 2023 - 2032	7.2%
Asia Pacific Diabetes Devices Market Analysis Period	2020 - 2032
Asia Pacific Diabetes Devices Market Base Year	2022
Asia Pacific Diabetes Devices Market Forecast Data	2023 - 2032
Segments Covered	By Type, By Distribution Channel, And By Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Roche Diabetes Care, Abbott Laboratories, Medtronic plc, Johnson & Johnson, Becton, Dickinson and Company, Novo Nordisk A/S, Sanofi S.A., Terumo Corporation, Ypsomed AG, and Ascensia Diabetes Care Holdings AG.
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Covid-19 Analysis, Regulation Analysis

Asia-Pacific Diabetes Devices Market Dynamics

Diabetes is a metabolic disorder that occurs due to high sugar levels in the blood, which are caused by either defect in the body’s ability to produce a sufficient amount of insulin or the incapability of body cells to respond to insulin. Based on the cause of development, diabetes is classified into three types, including Type 1 diabetes (pancreas stops producing insulin), Type 2 diabetes (body cells do not respond to the insulin), and Type 3 gestational diabetes (which occurs in pregnant women). Among these, Type 2 diabetes is the most common form of diabetes, occurring in approximately 90% of total patients. Type 1 diabetes is usually diagnosed in children and young adults, and has been treated by injection of insulin. Type 2 diabetes commonly affects older adults and youth; however, it can be initially managed with exercise and diet. During the course of time, most patients need oral medication for treatment. The International Diabetes Federation (IDF) estimated that the number of diabetes patients would reach around 640 million by 2040 from 415 million in 2015. In addition, IDF estimated that the global healthcare expenditure on diabetes care would surpass $802 billion by 2040 from $673 billion in 2015, which represents 12% of the overall healthcare spending.

Asia-Pacific Diabetes Devices Market Segmentation                                     

The Asia-Pacific diabetes device market segmentation is based on type, distribution channel, and geography.

Diabetes Devices Market By Type

• BGM Devices
  • Self-Monitoring Devices
    • Lancets
    • Blood Glucose Meters
    • Testing Strips
  • Continuous Glucose Monitoring Devices
    • Receiver
    • Sensors
    • Transmitters
• Insulin Delivery Devices
  • Jet Injectors
  • Pumps
  • Syringes
  • Pens

According to an Asia-Pacific diabetes devices industry analysis, the insulin delivery devices segment is a significant and rapidly growing segment in the market. Insulin delivery devices are used to administer insulin to people with diabetes, either through injections or insulin pumps. There are several types of insulin delivery devices, including insulin pens, insulin syringes, insulin pumps, and insulin jet injectors. Insulin pens are the most commonly used type of insulin delivery device, as they are easy to use and offer a more discreet way of administering insulin compared to syringes. Insulin pumps are another popular type of insulin delivery device, which deliver insulin continuously through a catheter placed under the skin. The insulin delivery devices market is expected to grow rapidly due to several factors, including the increasing prevalence of diabetes worldwide, the rising adoption of insulin pumps, and the development of advanced insulin delivery technologies.

Diabetes Devices Market By Distribution Channel

• Hospital pharmacies
• Online Pharmacies
• Diabetes Clinics/Centers
• Retail Pharmacies
• Others

According to the Asia-Pacific diabetes devices market forecast, the online pharmacies segment is expected to grow significantly in the coming years. Online pharmacies are websites or mobile applications that allow consumers to purchase diabetes devices and supplies online, often with home delivery options. The online pharmacies segment is growing rapidly due to several factors, including the increasing adoption of e-commerce and digital technologies, the convenience of online shopping, and the availability of a wide range of diabetes devices and supplies at competitive prices. Online pharmacies offer a convenient way for people with diabetes to purchase diabetes devices and supplies from the comfort of their homes, without having to visit physical pharmacies or medical stores. In addition, online pharmacies offer several advantages over traditional pharmacies, including 24/7 availability, a wider range of products, competitive pricing, and personalized services such as home delivery and refill reminders.

Asia-Pacific Diabetes Devices Market Player

Some of the top Asia-Pacific diabetes devices market companies offered in the professional report includes Roche Diabetes Care, Abbott Laboratories, Medtronic plc, Johnson & Johnson, Becton, Dickinson and Company, Novo Nordisk A/S, Sanofi S.A., Terumo Corporation, Ypsomed AG, and Ascensia Diabetes Care Holdings AG.

TABLE OF CONTENT